These Mid and Small Cap Shares to Trade Ex-Date on April 25: Do You Own Any?

On April 25, 2025, Muthoot Finance shares will trade ex-date, meaning that the shareholders registered in the company’s books will be eligible for the ₹26 interim dividend. In addition, the leading pharmaceutical giant, Sanofi India shares, will trade ex-date as it has fixed the record date for its ₹117 final dividend as April 25.

Dividend History

Management Take on Financials

Muthoot Finance

Mr. George Jacob Muthoot, Chairman, The Muthoot Group, said, “We are glad to report continued growth momentum on a quarter-on-quarter basis with our Consolidated Loan Assets Under Management crossing another milestone of Rs. 1,11,000 crores, while our Standalone Loan AUM surpassing Rs. 97,000 crores. The contribution of subsidiaries stands at 14%. Additionally, our Consolidated Profit after Tax for 9M FY25 increased by 19% YoY to Rs. 3,908 crores. Amid favourable macroeconomic indicators, the union budget’s positive tax reform announcements are expected to start a consumption cycle, combined with a steadfast commitment to the fiscal deficit target, the general economic outlook looks promising.

Also Read: Muthoot FinCorp Joins Hands with BankBazaar to Launch Digital Gold Loans

Sanofi India Limited

Rodolfo Hrosz, Managing Director, Sanofi India Limited “In a year of significant transformation for the company, we have successfully brought to market Soliqua® – our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts to reach more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.